{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:27:43Z","timestamp":1793870863688,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtocrr.2026.101005","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:06:13Z","timestamp":1776755173000},"page":"101005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single- Versus Multi-Fraction Stereotactic Body Radiotherapy for Primary Lung Cancer and Pulmonary Oligometastases: A Systematic Review and Meta-Analyses"],"prefix":"10.1016","volume":"7","author":[{"given":"Ishaan","family":"Pillay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101005_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2013.09.006","article-title":"Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort","volume":"109","author":"Sold\u00e0","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib4","article-title":"Is single fraction the future of stereotactic body radiation therapy (SBRT)? a critical appraisal of the current literature","volume":"39","author":"Terlizzi","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/cancers14030790","article-title":"Systematic review of single-fraction stereotactic body radiation therapy for early stage non-small-cell lung cancer and lung oligometastases: how to stop worrying and love one and done","volume":"14","author":"Bartl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2026.101005_bib6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s12094-021-02619-4","article-title":"A multi-institutional analysis of fractionated versus single-fraction stereotactic body radiotherapy (SBRT) in the treatment of primary lung tumors: a comparison between two antipodal fractionations","volume":"23","author":"Alongi","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib7","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (Safron II): the Trans Tasman Radiation Oncology Group 13.01 Phase 2 randomized clinical trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtocrr.2026.101005_bib9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized Phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with Stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtocrr.2026.101005_bib10","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2022"},{"key":"10.1016\/j.jtocrr.2026.101005_bib11","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Metaanalyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.jtocrr.2026.101005_bib12","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"205","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019"},{"key":"10.1016\/j.jtocrr.2026.101005_bib13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/bmjqs-2013-002246","article-title":"Estimating risk when zero events have been observed","volume":"22","author":"Quigley","year":"2013","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jtocrr.2026.101005_bib14","article-title":"DigitizeIt\u2014plot digitizer software","year":"2020","journal-title":"Digitize graphs, charts and math data"},{"key":"10.1016\/j.jtocrr.2026.101005_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jtocrr.2026.101005_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jtocrr.2026.101005_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtocrr.2026.101005_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/insr.12000","article-title":"Confidence distribution, the frequentist distribution estimator of a parameter: a review","volume":"81","author":"Xie","year":"2013","journal-title":"Int Stat Rev"},{"key":"10.1016\/j.jtocrr.2026.101005_bib20","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.cllc.2017.10.010","article-title":"Comparison of single- and three-fraction schedules of stereotactic body radiation therapy for peripheral early-stage non-small-cell lung cancer","volume":"19","author":"Ma","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101005_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1017\/S1460396917000061","article-title":"Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience","volume":"16","author":"Ma","year":"2017","journal-title":"J Radiother Pract"},{"key":"10.1016\/j.jtocrr.2026.101005_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.06.005","article-title":"Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review","volume":"129","author":"Kobiela","year":"2018","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib23","article-title":"Radioresistant pulmonary oligometastatic and Oligoprogressive lesions from nonlung primaries: impact of histology and dose-fractionation on local control after radiation therapy","volume":"9","author":"Verma","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pro6.5","article-title":"Molecular effectors of radiation resistance in colorectal cancer","volume":"1","author":"Geng","year":"2017","journal-title":"Precis Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582239","article-title":"Downregulation of miR-423-5p contributes to the radioresistance in colorectal cancer cells","volume":"10","author":"Shang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101005_bib27","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.ijrobp.2011.01.038","article-title":"Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer","volume":"81","author":"Olsen","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtocrr.2026.101005_bib28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jamaoncol.2023.3495","article-title":"Individualized stereotactic ablative radiotherapy for lung tumors: the iSABR phase 2 nonrandomized controlled trial","volume":"9","author":"Gensheimer","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:57:58Z","timestamp":1793869078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666364326000561"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101005","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single- Versus Multi-Fraction Stereotactic Body Radiotherapy for Primary Lung Cancer and Pulmonary Oligometastases: A Systematic Review and Meta-Analyses","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101005"}}